Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Lymphatics
Special Issues
Indolent Lymphomas and Lymphoreticular Proliferative Diseases
share announcement

Indolent Lymphomas and Lymphoreticular Proliferative Diseases

A special issue of Lymphatics (ISSN 2813-3307).

Deadline for manuscript submissions: closed (30 September 2025) | Viewed by 1017

Special Issue Editor

Dr. Chi Sing Ng

E-Mail Website
Guest Editor
Caritas Medical Centre Hong Kong, Hong Kong, China
Interests: viral oncogenesis; NK/T-cell lymphomas; immunology; immunoglobulin-related fibroinflammatory diseases

Special Issue Information

Dear Colleagues,

Indolent lymphomas (ILs) and lymphoreticular proliferative diseases (ILPDs) are characterized by running protracted courses with intermittent remissions and relapses. They may be unicentric, affecting a single site, or multicentric, affecting multiple organ systems with systemic biochemical and hematologic manifestations. ILs and ILPDs are clinically non-aggressive and histologically localized or minimally invasive and low-grade. ILPDs may be polyclonal, oligoclonal, or monoclonal. ILs and ILDs arise from cells of B-, NK (natural killer)-, T-, or dendritic lineages. Though they are indolent, progression to overt lymphoma can occur in ILPDs, and high-grade transformation can arise in ILs, requiring continuous monitoring and prompt treatment. This Special Issue will cover the broad range of ILs and ILPDs and their different and nuanced morphology, immunophenotypes, genetics, clinical behaviors, and therapeutic options.

Dr. Chi Sing Ng
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Lymphatics is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • indolent lymphomas
  • lymphorecticular proliferative diseases
  • immunophenotype
  • genetics
  • clinical behavior
  • lymphoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

18 pages, 2934 KB  
Review
Indolent T- and Natural Killer-Cell Lymphomas and Lymphoproliferative Diseases—Entities in Evolution
by Chi Sing Ng
Lymphatics 2025, 3(4), 41; https://doi.org/10.3390/lymphatics3040041 - 29 Nov 2025
Viewed by 131
Abstract
Indolent lymphoproliferative diseases or disorders (LPDs) derived from T cells or Natural Killer (NK) cells may be neoplastic or non-neoplastic, which are often difficult to distinguish from each other and from their aggressive counterparts. The etiology and pathogenesis are mostly nebulous and may [...] Read more.
Indolent lymphoproliferative diseases or disorders (LPDs) derived from T cells or Natural Killer (NK) cells may be neoplastic or non-neoplastic, which are often difficult to distinguish from each other and from their aggressive counterparts. The etiology and pathogenesis are mostly nebulous and may be related to infections or immune dysfunction. Indolent lymphomas differ from the high-grade aggressive counterparts by a prolonged clinical course of persistent or relapsing disease, histology, immunophenotype, and genetics. In recent decades, indolent lymphomas or LPD of T or NK cell derivation have been increasingly recognized, causing diagnostic and nosologic confusion. The issue is particularly challenging in the arena of indolent intestinal lymphomas and LPD, as evidenced by the myriad of names given to the indolent intestinal T- and NK-cell lymphomas and LPD. Confounding the picture are also reports of Epstein–Barr virus (EBV) positivity in various indolent non-intestinal LPD and, rarely, even in indolent intestinal T-cell lymphoma, which have been widely accepted to be typically EBV-negative. This review aims to curate current information and understanding of these diseases with the goal of resolving these issues. The recently described indolent T-lymphoblastic proliferation (iTLBP) and the re-classified indolent primary cutaneous CD4-positive small or medium T-cell LPDs and primary cutaneous acral CD8-positive T-cell LPDs also require greater awareness and recognition. It is important to diagnose these indolent entities in order to avoid over-treatment and unnecessary therapeutic intervention and to provide for accurate prognostic prediction and appropriate follow-up. Full article
(This article belongs to the Special Issue Indolent Lymphomas and Lymphoreticular Proliferative Diseases)
►▼ Show Figures

Graphical abstract

Other

Jump to: Review

6 pages, 1522 KB  
Case Report
Lymphomatoid Granulomatosis and Tuberculosis, Coincidence or Cohabitation—A Case Report
by Nicolas Giachetti, Sarah Bellal, Marianne Schwarz, Jérôme Paillassa, Aline Clavert, Mathilde Hunault-Berger and Firas Safa
Lymphatics 2025, 3(3), 28; https://doi.org/10.3390/lymphatics3030028 - 15 Sep 2025
Viewed by 563
Abstract
Background: Lymphomatoid granulomatosis (LYG) is a rare and atypical EBV-induced B-cell lymphoproliferative disorder. Clinical manifestations are mainly respiratory, with nodular infiltrates, varying in number and size, being responsible for respiratory distress. Cutaneous, hepatic, or neurological involvement is also possible. Although pathogenesis is not [...] Read more.
Background: Lymphomatoid granulomatosis (LYG) is a rare and atypical EBV-induced B-cell lymphoproliferative disorder. Clinical manifestations are mainly respiratory, with nodular infiltrates, varying in number and size, being responsible for respiratory distress. Cutaneous, hepatic, or neurological involvement is also possible. Although pathogenesis is not clearly elucidated, quantitative or qualitative cellular immunodepression is thought to be a main factor. Here, we report a case of concomitant LYG and pulmonary tuberculosis. Case presentation: An 80-year-old female patient presented to the emergency unit for steadily increasing dyspnea, with workup revealing bilateral pulmonary nodules and mediastinal lymph node enlargement on chest imaging. Empiric antibiotic therapy was initially started with amoxicillin-clavulanate, which was later combined with azithromycin following respiratory deterioration. A CT-guided lung biopsy showed grade 2 LYG. Treatment with corticosteroids and weekly rituximab was initiated, leading to rapid improvement of respiratory symptoms. After the second dose of rituximab, sputum cultures that were initially collected were found to be positive for Mycobacterium tuberculosis. Rituximab was suspended, and antituberculous treatment was initiated. Rituximab was restarted once tuberculosis was controlled. Follow-up imaging later showed adequate control of both tuberculosis and LYG, with at least a partial remission of the latter. Conclusions: Our case highlights the importance of a complete diagnostic workup when a diagnosis of LYG is made, to avoid missing a concomitant pulmonary disease, such as tuberculosis, even when definite pathologic and clinical features of the former are present. Full article
(This article belongs to the Special Issue Indolent Lymphomas and Lymphoreticular Proliferative Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop